TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
28.065
-0.150 (-0.532%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close28.215
Open28.015
Bid0.000 x 0
Ask0.000 x 0
Day's Range27.925 - 28.150
52 Week Range19.960 - 28.400
Volume23,401
Avg. Volume78,741
Market Cap43.76B
Beta0.40
PE Ratio (TTM)30.11
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2016-09-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube29 days ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017
    Capital Cubelast month

    Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Takeda Pharmaceutical Co., Ltd. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Takeda Pharmaceutical Co., Ltd. – Pfizer Inc., Amgen Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Seattle Genetics, Inc., Sanofi Sponsored ADR, Dr. Reddy’s Laboratories Ltd. ... Read more (Read more...)

  • The Wall Street Journallast month

    [$$] Takeda Pharmaceutical’s CEO Prescribes Stability After Rough Start

    Takeda CEO Christophe Weber said another multibillion-dollar acquisition was unlikely soon, allaying fears Japan’s largest drugmaker was building up too much debt.

  • We want to globalize our products and our company, Takeda Pharmaceutical CEO says
    CNBC2 months ago

    We want to globalize our products and our company, Takeda Pharmaceutical CEO says

    Globalization has been key to Takeda Pharmaceutical's strategy to achieving growth, its CEO said.

  • GuruFocus.com2 months ago

    FDA to Review Amgen's Supplement Application for Kyprolis

    Company seeks to add overall survival data

  • The Wall Street Journal2 months ago

    [$$] Samsung Broadens Its Drugs Business

    The Samsung conglomerate is furthering its efforts to build a full-fledged prescription-drugs business, signing its first deal to develop novel drugs for hard-to-treat diseases.

  • Market Realist2 months ago

    How Celgene’s Pomalyst Is Positioned after 2Q17

    In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.

  • Capital Cube3 months ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : August 4, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Seattle Genetics (SGEN) Q2 Loss Narrower than Expected
    Zacks3 months ago

    Seattle Genetics (SGEN) Q2 Loss Narrower than Expected

    Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.

  • Reuters3 months ago

    Nikkei falls to more than 1-week lows as cyclical stocks weigh; Toshiba jumps

    Japan's Nikkei share average fell to a more than one-week low on Tuesday morning after cyclical stocks lost ground as a stronger yen hit sentiment, while Toshiba Corp rallied after news a U.S. hedge fund ...

  • Reuters3 months ago

    U.S. court upholds Takeda patent on cancer drug Velcade

    A U.S. appeals court ruled on Monday that a patent on Takeda Pharmaceutical Co Ltd's cancer treatment Velcade is valid, pushing back the date when generic drug makers including Teva Pharmaceutical Industries Ltd and Mylan NV will be allowed to launch lower-cost versions of the drug in the United States. The U.S. Court of Appeals for the Federal Circuit rejected arguments by a dozen generic drug companies that the Velcade patent was obvious and should not have been granted. The ruling, which reversed a lower court, will allow Takeda to sell Velcade exclusively until the patent expires in 2022.

  • Moody's3 months ago

    Takeda Pharmaceutical Company Limited -- Moody's assigns A1 rating to Takeda Pharmaceutical's USD notes

    Rating Action: Moody's assigns A1 rating to Takeda Pharmaceutical's USD notes. Global Credit Research- 13 Jul 2017. USD500 million of new debt rated.

  • Pill-Popping Is a Business Worth Watching for Japan's Drugmakers
    Bloomberg3 months ago

    Pill-Popping Is a Business Worth Watching for Japan's Drugmakers

    To eke out growth in one of the developed world’s most sluggish pharmaceutical markets, Japanese drugmakers are turning to the pill-popping behavior of their customers.

  • Capital Cube4 months ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : July 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q4, 2017 By the Numbers : July 4, 2017
    Capital Cube4 months ago

    Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q4, 2017 By the Numbers : July 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Takeda Pharmaceutical Co., Ltd. reports financial results for the quarter ended March 31, 2017. Highlights Summary numbers: Revenues of USD 3,664.99 million, Net Earnings of USD -446.75 million. Gross margins widened from 60.15% to 60.38% compared to the same period last year, operating (EBITDA) margins now 8.25% from 8.16%. Change in ... Read more (Read more...)

  • Japan's Cushy Retirement Gigs Face Greater Scrutiny
    Bloomberg4 months ago

    Japan's Cushy Retirement Gigs Face Greater Scrutiny

    For decades, Japanese boards allowed former executives to linger on in highly paid advisory roles, without offering shareholders much detail. Now, there are signs that cushy retirement gigs may no longer ...

  • Seattle Genetics (SGEN) Reports Positive Data for Adcetris
    Zacks4 months ago

    Seattle Genetics (SGEN) Reports Positive Data for Adcetris

    Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.

  • InvestorPlace4 months ago

    Why Stratasys, Ltd. (SSYS), Arconic Inc (ARNC) and Seattle Genetics, Inc. (SGEN) Are 3 of Today’s Worst Stocks

    It could have been worse though — you could have owned Stratasys, Ltd. (NASDAQ:SSYS), Arconic Inc (NYSE:ARNC) and Seattle Genetics, Inc. (NASDAQ:SGEN). Seattle Genetics shareholders got the new trading week started on the wrong foot, with SGEN sliding 8.4% following reports that one of its cancer drug trials didn’t quite live up to expectations. The drug, called Adcetris, was being co-developed by Japanese biopharma outfit Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) as a therapy for certain forms of blood cancer.

  • Reuters4 months ago

    UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors

    Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening. The study testing the combination as an initial treatment for advanced Hodgkin's lymphoma showed 82.1 percent lower risk of cancer progression in patients, compared with 77.2 percent in the control arm. The control arm used standard-of-care chemotherapy, ABVD, which combines adriamycin, bleomycin, vinblastine and dacarbazine drugs.

  • Reuters4 months ago

    Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial

    Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening. The study tested Adcetris in combination with a three-drug chemotherapy regimen, AVD, compared with standard of care, to treat advanced Hodgkin's lymphoma in 1,334 patients who have had no prior treatments. Adcetris is already approved in the United States to treat patients with classical Hodgkin's lymphoma, who have already received a stem cell transplant or two chemotherapy treatments.

  • Market Realist4 months ago

    Why Lupron Could Continue to Generate Steady Revenue

    In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

  • Market Realist5 months ago

    Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017

    Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.

  • We are in recovery mode: Takeda CEO
    CNBC Videos2 months ago

    We are in recovery mode: Takeda CEO

    Christophe Weber, CEO of Takeda Pharmaceutical, talks about how innovation and globalization will help the Japanese company grow in the future.